Hemagglutinin protein of Influenza A virus subtype H9 (HA (H9))

The **hemagglutinin protein of Influenza A virus subtype H9** (HA H9) is a trimeric surface glycoprotein essential for viral infectivity. It mediates the initial attachment of the virus to host cells by binding to sialic acid–containing receptors and facilitates fusion of the viral envelope with host membranes after endocytosis and acidification[1][3][4][6]. Structurally, each HA monomer is cleaved into two subunits (HA1 and HA2) that form a metastable prefusion complex; a conformational change at low pH exposes the fusion peptide in HA2, triggering membrane fusion[2][3][5][6]. HA H9 is highly antigenic, eliciting neutralizing antibodies that may block viral entry or fusion[4]. Due to its crucial role in viral entry, HA is a key target for vaccine development and therapeutic antibodies; it is also central in subtype-specific surveillance, as H9 strains can transmit from birds or swine to humans[2][3][6]. Mutation and antigenic variability, particularly in the receptor-binding site and adjacent antigenic loops, complicate sustained immune protection and present ongoing challenges for vaccine design and pandemic preparedness[1][6]. **Note**: - There are no currently approved small-molecule drugs that specifically target HA H9, but experimental therapies (e.g., monoclonal antibodies, fusion inhibitors) have shown efficacy in preclinical or limited clinical contexts[4][6]. - HA presence and antibody titers are used as biomarkers for infection and vaccine-induced immunity; hemagglutinin inhibition assays are standard diagnostic tools[4]. - Antigenic drift (mutation) and shift (reassortment) may allow H9 strains to evade antibodies, necessitating ongoing surveillance and updating of vaccine compositions[4][6].

Other names

Influenza A virus hemagglutinin H9HA H9H9 subtype hemagglutininInfluenza A H9 HA

Binding or blocking the receptor-binding site to prevent viral attachment - Inhibiting acid-induced conformational rearrangement to block membrane fusion - Neutralization by antibodies targeting head or stem of hemagglutinin